← board
XOMAP
distress 1/10 · well-funded / low risk$24.980%today-8% from 52w high
Lead: pulmonary arterial hypertension · est. market ~$25B (approx, global)
Revenue
$12M
Liquidity
$86M
Runway
—
Shares 1y
+4%
Price & events
-1.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.3%
1M
-2.4%
3M
-1.1%
6M
+6.0%
1Y
+16.0%
2Y
+47.3%
5Y
+59.1%
All
Overview
- Market Cap
- $313.27M
- Enterprise Value
- $316.50M
- Volume
- 0
- 52 Week Range
- $24.96 – $27.25
- Total Shares
- 12.54M
- Float Shares
- 4.80M
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 1.02%
- Beta
- 0.86
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- 2026Guided 40%readoutPhase 2seralutinib · Phase 2b data announcementSEC 8-K
- second half of 2026Guided 55%readoutPhase 3ersodetug · Phase 3 topline results from upLIFT studySEC 8-K
- second half of 2026Guided 55%enrollment completesecondaryPhase 2volixibat · Enrollment completion for VANTAGE studySEC 8-K
- 2026Guided 40%readoutPhase 1/2REC-4881 · Phase 1/2 data announcementSEC 8-K
- on or about July 14, 2026Confirmed 100%trial initiationsecondaryExpected closing of acquisition by LigandSEC 8-K
- Q2 2026readoutPhase 2volixibat · Phase 2b topline data from VISTAS studySEC 8-K
- fourth quarter of 2025readoutPhase 3seralutinib · Phase 3 study topline readoutSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — pulmonary arterial hypertension
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- PFEPFIZER INC$142.2B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- INSMINSMED Inc$22.9B · D2
- UTHRUNITED THERAPEUTICS Corp$22.3B · D0
- IKTInhibikase Therapeutics, Inc.$289M · D4
- KROSKeros Therapeutics, Inc.$197M · D2
- GOSSGossamer Bio, Inc.$33M · D5
Recent news
- 2026-07-23XOMA Royalty Corp SEC Filing (Jul 23, 2026) - Stock Titan
- 2026-07-23Mobileye Announces Planned Leadership Transition - Business Wire
- 2026-07-23Matador Resources Company Announces Strategic Delaware Basin Acquisitions and Successful Woodford Exploration Well Results - Business Wire
- 2026-07-22Domo Announces Agreement to Sell Substantially All Assets and Certain Liabilities to Progress Software for $400 Million - Business Wire
- 2026-07-21CapVest Completes Acquisition of TSG - Business Wire
- 2026-07-20XOMA (XOMA) removes unsold securities after $200M shelf and merger - Stock Titan
- 2026-07-20Magnolia Oil & Gas Announces Acquisition of WildFire Energy - Business Wire
- 2026-07-17NYSE American to Commence Delisting Proceedings Against Nuburu, Inc. (BURU) - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.